Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Targeting Triple Negative BREAst Cancer Metabolism With a Combination of Chemoimmunotherapy and a FASTing-like Approach in the Preoperative Setting: the BREAKFAST 2 Trial

NCT05763992 is registered in ClinicalTrials.gov with Fondazione IRCCS Istituto Nazionale dei Tumori, Milano as lead sponsor.

NCT NCT05763992
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05763992 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Targeting Triple Negative BREAst Cancer Metabolism With a Combination of Chemoimmunotherapy and a FASTing-like Approach in the Preoperative Setting: the BREAKFAST 2 Trial
Lead sponsor
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase
Phase 2
Overall status
Unknown status
Start date
May 15, 2023
Completion date
May 15, 2026
Enrollment
145 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, dietary exposure, fasting, triple negative breast cancer